达格列酮
达格列酮 性质
| 密度 | 1.306±0.06 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO:20.0(最大浓度 mg/mL);47.56(最大浓度 mM) DMF:20.0(最大浓度 mg/mL);47.56(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 6.22±0.50(Predicted) |
| 颜色 | 白色至浅黄色 |
达格列酮 用途与合成方法
|
PPAR-γ
|
In cell lines representing white (3T3-L1 and 3T3-F442A) and brown (HIB-1B) adipose tissues and skeletal muscle (L6), within 4 h of exposing these cells to 30 μM Darglitazone, there is an increase in uncoupling protein 2 (UCP2) mRNA which reached a plateau of 5-10 times the basal in about 8 h. Darglitazone can stimulate the expression of UCP2 gene probably via PPAR-γ.
Darglitazone treatment restores euglycemia and normalized elevated corticosterone, triglycerides, and very-low-density lipoprotein levels. Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24 h of recovery. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult.
| Animal Model: | Male diabetic ob/ob mice |
| Dosage: | 1 mg/kg |
| Administration: | Oral administration; daily; for 7 days |
| Result: | Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice. |
达格列酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-08-19 | HY-120160 | 5 mg | 1100 | ||
| 2024-08-19 | HY-120160 | 10 mg | 1800 |
